Transaktionen anzeigen
Private Equity | Gesundheitswesen

Hemideina has raised funds via a private placement

Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.

Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.

Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.

DIENSTLEISTUNG
Beschaffung von Kapital
PARTEIEN
«I’d like to extend my thanks to the team for managing the raise, as well as our team. The high-caliber work completed to date has built confidence around our technology with investors and continues to be the key to our success.»

Elizabeth Williams

CEO and co-founder, Hemideina

Sprechen Sie mit dem Deal Team

Jonathan Tooth

Jonathan Tooth

Director
Melbourne, Australien
Oaklins Henslow
Kurzprofil Kontakt aufnehmen
Ryan Whitelegg

Ryan Whitelegg

Managing Director
Melbourne, Australien
Oaklins Henslow
Kurzprofil Kontakt aufnehmen

Transaktionen

Valmiermuižas Alus has been acquired by Cēsu Alus
Private Equity | Lebensmittel- und Getränkeindustrie

Valmiermuižas Alus has been acquired by Cēsu Alus

Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.

Mehr erfahren
Die Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland
Gesundheitswesen

Die Lindenhofgruppe veräussert ihre Mehrheitsbeteiligung an der LabPoint an Affidea Switzerland

Die LabPoint Medizinische Laboratorien AG wurde von Affidea Switzerland AG übernommen. Mit Affidea hat die Lindenhofgruppe AG einen starken strategischen Partner für die Weiterentwicklung der LabPoint gewonnen. Die Lindenhofgruppe bleibt bedeutende Aktionärin und Grosskundin des Unternehmens. Damit schafft sie die Grundlage für eine nachhaltige Weiterentwicklung von LabPoint unter einer neuen Ankeraktionärin. LabPoint soll ihre Position in der Labordiagnostik weiter stärken und gezielt ausbauen.

Mehr erfahren
Armira has signed an agreement to acquire a majority stake in Viabus
Private Equity | Handel

Armira has signed an agreement to acquire a majority stake in Viabus

Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.

Mehr erfahren